FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses
The latest: Legend Biotech Corp. (LEGN.US) announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration…
Recent Articles
RELATED ARTICLES
-
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
1548.HK LEGN.US -
NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
LEGN.US
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
-
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US 6160.HK 688235.SHG
- Sunho Biologics gets green light for downsized IPO
